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Clinical practice guidelines are intended to help practitioners 
and patients select the diagnostic and therapeutic approaches 
that are best supported by the evidence. Guidelines are par-
ticularly useful in the context of evolving research, as they 
free practitioners from the burden of personally evaluating 
the often overwhelming corpus of knowledge [1, 2]. When 
high-level evidence is unavailable, guidelines rely on expert 
consensus to resolve uncertainty.
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Despite their utility, guideline documents usually explic-
itly disavow the intent to establish a standard of care [3, 
4]. This is not a manifestation of false modesty, but a rec-
ognition that no guidelines, no matter how comprehensive 
and carefully crafted, cannot foresee every circumstance. 
Patients may differ in terms of their genetic predisposition, 
susceptibility to disease, and co-morbidities; disease pro-
cesses may vary in their manifestations, and may include 
overlap with other diseases or syndromes; at the time of 
diagnosis, the disease process may be incipient or advanced, 
along a spectrum of disease severity or stage; prior treat-
ments may have rendered infeasible otherwise appropriate 
treatment options; patients competent to participate in their 
care may decline certain options; or resource availability or 
local expertise may suggest the primacy of particular, non-
standard diagnostic or therapeutic interventions.
In some cases, it may not be possible for guidelines to 
provide relevant recommendations. For instance, evidence 
regarding a particular clinical circumstance may be lacking; 
research on disease management in socially or economically 
diverse populations may be insufficient; or certain drugs or 
therapies may be too new to judge reliably [5].
Given these inherent limitations of clinical practice 
guidelines, it has been suggested that guidelines should be 
concise and not longer than a few pages [6]. Beyond provid-
ing general recommendations as well as some more detailed 
guidance when is necessary and supported by evidence, 
guidelines should defer to the clinical wisdom of the expe-
rienced physician.
One question that remains unsettled is what proportion of 
cases of a disease or condition should be covered by clini-
cal practice guidelines. The National Comprehensive Cancer 
Network has suggested that its cancer guidelines apply to 
95% of cases. Other organizations have been less specific 
about clarifying the breadth of their guidelines.
Theoretically, guidelines can be stratified by severity of 
disease, or even by stage. However, in general, guidelines are 
created for a disease or condition, not a specific manifesta-
tion or severity level. The same is true for cancer guidelines.
There are reasons why more specific cancer guidelines 
are not practical [7, 8]. While it is difficult to develop guide-
lines that apply consistently to the broad majority of patients 
with a particular type of cancer, it is even more challenging 
to refine these guidelines for individual subsets of patients. 
First, evidence for management of very specific patient sub-
populations is necessarily sparse. This dearth of evidence 
becomes progressively more of a barrier as the specificity of 
the cancer subgroup increases. Second, there are very many 
specific subsets of cancer patients for which guidelines could 
be developed. If only a few such categories are addressed, 
the guidelines will not collectively be comprehensive. 
Alternatively, if many variants are separately addressed, the 
guidelines will be so cumbersome and long as to be of little 
use. Third, defining the bounds of subsets of cancer patients 
is fraught. Major divisions, such as local versus metastatic 
disease, or AJCC stages, are generally accepted. However, 
more fine categories are necessarily created by the guideline 
makers. This is problematic, since the purpose of practice 
guidelines is not to create nomenclature and categories, but 
to explain how patients in generally accepted categories 
should be managed. Fourth, guidelines for small subsets of 
cancer patients will necessarily be applicable to only a few 
patients. The effort and expense required to develop and 
update such specific guidelines may not be commensurate 
with the degree of benefit accruing to the small group to 
which they apply. Health care resources are a precious com-
modity, and may be better deployed in other ways to help 
patients. Fifth, since one important function of guidelines 
is to convince regulators and payers of the need to permit 
and reimburse medically necessary procedures, excessively 
narrow guidelines for a small subset can backfire. The very 
specificity of such guidelines implies that diagnostic or treat-
ment procedures not envisioned in the guidelines are inap-
propriate and should not be paid for by insurers. The produc-
ers of extremely detailed guidelines cannot simultaneously 
credibly argue that interventions not explicitly endorsed by 
their guidelines should also be allowed because the guide-
lines are general in scope, with many clinical circumstances 
excluded.
Clinical practice guidelines for the 1% of most severe 
cases are, thus, not helpful to the patients they wish to 
describe. Rather, guidelines are useful when they are broadly 
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applicable, and do not address only particular severity levels 
or new categories of their own creation. Specifically, ideal 
guidelines apply to most but not all patients with a disease 
or condition. 5–10% of the least affected and most affected 
patients, respectively, may be excluded from the guidelines. 
Extreme cases at either end of the severity spectrum will 
need to be treated differently than the large majority between 
these poles. Including in the guidelines written estimates 
of the proportion and type of patients not covered will be 
helpful to all users, including providers, patients, payers, and 
regulators. Such delineation of the scope of the guidelines 
will also allow for a brief, cohesive document in which dis-
cussion of every therapeutic approach is not qualified with 
exceptions and disclaimers.
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